Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets

Fineline Cube Apr 27, 2026
Company Deals

China Resources Double-Crane to Acquire Nanjing Xinbai Pharma from Boya Biological for RMB 235.5 Million, Expanding Injectables Portfolio

Fineline Cube Apr 27, 2026
Company Deals

Johnson & Johnson Acquires Atraverse Medical to Expand Cardiac Ablation Portfolio with Next-Gen Left-Heart Access Technology

Fineline Cube Apr 27, 2026
Company Deals

Star Sports Medicine Raises HKD 830 Million in Hong Kong IPO as China’s Leading Domestic Sports Medicine Provider

Fineline Cube Apr 24, 2026
Company Deals

Sisram Medical Forges Strategic Alliance for Daxxify Commercialization in China’s Long-Acting Botulinum Toxin Market

Fineline Cube Apr 24, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

CSPC Pharmaceutical Receives FDA Clearance to Launch First-in-Class KAT6 Inhibitor SYH2095 Clinical Trial for Advanced Cancers

Fineline Cube Apr 27, 2026
Company Drug

Bristol-Myers Squibb and Pfizer Partner with Mark Cuban’s Cost Plus Drugs to Offer Eliquis at $345 for 30-Day Supply, Expanding Access to Blockbuster Anticoagulant

Fineline Cube Apr 27, 2026
Policy / Regulatory

Shaanxi Leads New Provincial Alliance for Volume-Based Procurement of Medical Products

Fineline Cube Aug 15, 2024

The Shaanxi Public Resources Trading Center has announced the formation of a provincial alliance for...

Company Drug

CStone to Manufacture Gavreto Locally Following NMPA Approval, Expanding Market Presence

Fineline Cube Aug 15, 2024

CStone Pharmaceuticals (HKG: 2616), a China-based biopharmaceutical company, has received approval from the National Medical...

Company Medical Device

China’s Sansure Biotech Launches Approved Kit for Alzheimer’s and Cardiovascular Risk Assessment

Fineline Cube Aug 15, 2024

Sansure Biotech Inc. (SHA: 688289), a China-based leader in molecular diagnostics, has secured marketing approval...

Company Drug

Qilu Pharmaceutical Gains Approval for Generic Dasatinib, Expanding CML Treatment Options in China

Fineline Cube Aug 14, 2024

Qilu Pharmaceutical, based in China, has received marketing approval for its generic version of Bristol-Myers...

Company

Eli Lilly Unveils $700 Million R&D Center in Boston to Boost Genetic Medicine Efforts

Fineline Cube Aug 14, 2024

Eli Lilly & Co. (NYSE: LLY) has inaugurated its new R&D center in Boston’s Seaport...

Company Drug

Ascentage Pharma Secures NMPA Approval for Phase III Trial of Lisaftoclax in MDS

Fineline Cube Aug 14, 2024

Ascentage Pharma (HKG: 6855), based in China, has received approval from the National Medical Products...

Company Drug

Enhertu Gains Conditional Approval in China for Advanced HER2-Positive Gastric Cancer

Fineline Cube Aug 14, 2024

Enhertu (trastuzumab deruxtecan), an HER2-targeted antibody-drug conjugate co-developed by AstraZeneca (NASDAQ: AZN, LON: AZN) and...

Company Deals R&D

New Agreement Enhances Myopia Solutions: Hong Kong Polytechnic and Zeiss Collaborate

Fineline Cube Aug 14, 2024

The School of Optometry at Hong Kong Polytechnic University has announced a new cooperation agreement...

Company Medical Device

Lepu Medical’s PeakHeat Vascular Sheath Gains Regulatory Green Light for Market Launch

Fineline Cube Aug 14, 2024

Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003), a leading provider of cardiovascular disease solutions...

Company Drug Legal / IP

Novartis Intensifies Legal Action Against FDA Over Entresto Generic Approval

Fineline Cube Aug 14, 2024

Novartis Inc. (NYSE: NVS) is intensifying its efforts to thwart the entry of generic competitors...

Company

Sino Biopharmaceutical Reports Record H1 Revenues of RMB 15.87 Billion, Net Profit Soars 139.7%

Fineline Cube Aug 14, 2024

Sino Biopharmaceutical Ltd (HKG: 1177) reported robust financial results for the first half of 2024,...

Company Drug

Wantai Biological’s HPV Vaccine Receives Priority Review from China’s CDE

Fineline Cube Aug 14, 2024

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd (SHA: 603392) has announced that its nine-valent recombinant...

Company Drug

Hengrui Pharmaceuticals Launches Phase II Trial for SHR7280 to Treat Uterine Fibroids

Fineline Cube Aug 14, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading Chinese pharmaceutical company, has received approval...

Company Legal / IP R&D

HuidaGene Secures Patent for Innovative CRISPR-Cas12i System in China

Fineline Cube Aug 14, 2024

HuidaGene (Shanghai) Biotechnology Co., Ltd, a China-based biotech firm, has secured patent approval from the...

Company Drug

GSK Initiates Phase III Study for RSV Vaccine in China Following U.S. Approval

Fineline Cube Aug 14, 2024

GSK (NYSE: GSK), the UK-based pharmaceutical giant, has registered a Phase III bridging study for...

Company Drug

Sihuan Pharmaceutical Secures NMPA Approval for First Biosimilars of Novo Nordisk’s Diabetes Drugs

Fineline Cube Aug 14, 2024

Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has secured separate marketing approvals from China’s National...

Company

Gilead Buys Out Janssen’s Royalty Rights to Seladelpar for Primary Biliary Cholangitis Treatment

Fineline Cube Aug 13, 2024

Gilead (NASDAQ: GILD)’s financial report for the second quarter of 2024, followed by an earnings...

Company

Legend Biotech CEO Addresses Biosecure Act Concerns Amid Q2 2024 Earnings Report

Fineline Cube Aug 13, 2024

Legend Biotech Corporation (Nasdaq: LEGN), a leading Chinese biopharmaceutical company, has released its financial results...

Company Deals

Ocumension Therapeutics Partners with Alcon Laboratories, Secures Rights to Ophthalmic Products in China

Fineline Cube Aug 13, 2024

Ocumension Therapeutics (HKG: 1477), a biopharmaceutical company based in China, has entered into a strategic...

Company Drug

Pfizer’s Hemophilia Treatment Marstacimab Accepted for Review in China

Fineline Cube Aug 13, 2024

The China Center for Drug Evaluation (CDE) has accepted for review a market approval filing...

Posts pagination

1 … 305 306 307 … 657

Recent updates

  • CSPC Pharmaceutical Receives FDA Clearance to Launch First-in-Class KAT6 Inhibitor SYH2095 Clinical Trial for Advanced Cancers
  • Bristol-Myers Squibb and Pfizer Partner with Mark Cuban’s Cost Plus Drugs to Offer Eliquis at $345 for 30-Day Supply, Expanding Access to Blockbuster Anticoagulant
  • Henlius Biotech Launches Phase II/III Trial in Australia for Triple Combination Therapy in Squamous NSCLC Featuring Novel Anti-EGFR Antibody Pimurutamab and Approved PD-1 Inhibitor HanSiZhuang
  • Novartis Secures WHO Pre-Qualification for Coartem Baby, First Antimalarial Specifically Designed for Newborns and Infants Under 5 kg
  • AstraZeneca Secures FDA Approval for Subcutaneous Saphnelo in Systemic Lupus Erythematosus After Addressing Supplemental Data Request
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

CSPC Pharmaceutical Receives FDA Clearance to Launch First-in-Class KAT6 Inhibitor SYH2095 Clinical Trial for Advanced Cancers

Company Drug

Bristol-Myers Squibb and Pfizer Partner with Mark Cuban’s Cost Plus Drugs to Offer Eliquis at $345 for 30-Day Supply, Expanding Access to Blockbuster Anticoagulant

Company Drug

Henlius Biotech Launches Phase II/III Trial in Australia for Triple Combination Therapy in Squamous NSCLC Featuring Novel Anti-EGFR Antibody Pimurutamab and Approved PD-1 Inhibitor HanSiZhuang

Company Drug

Novartis Secures WHO Pre-Qualification for Coartem Baby, First Antimalarial Specifically Designed for Newborns and Infants Under 5 kg

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.